

**Elekta optimizes treatment times for cancer patients via proactive service innovation**  
*Elekta in the forefront of service innovation through first radiotherapy system availability patent*

STOCKHOLM – For the last several years, Elekta (EKTA-B.ST) has invested substantially in digitized service solutions to keep critical treatment machines up and running at cancer clinics, thereby ensuring that patients receive timely radiotherapy. Among these solutions is the remote exchange of technical system data between Elekta remote service centers and linear accelerators installed at hospitals worldwide.

Using Elekta [IntelliMax®](#) real-time, remote system data monitoring, Elekta keeps a watchful eye on more than 80 percent of the company’s linear accelerators installed around the world. IntelliMax constantly tracks these systems’ functionality and technical status to ensure timely prevention or repair of issues. Elekta recently received its first patent for an IntelliMax capability that can help radiotherapy departments preserve the functionality of a crucial component of the technology used to treat patients.

**Service innovation supports Access 2025 strategy**

“Innovations such as IntelliMax are in harmony with our overall service strategy,” says Paul Bergström, Executive Vice President, Global Service. “As our technology advances, it is critical to ensure its serviceability and maintenance progresses. Elekta is changing the equipment service paradigm – rather than responding reactively, our service model is centered on our strategy of lifelong partnership with our customers, proactively ensuring treatment systems are available when needed. Through IntelliMax, we can attend to systems during hours when it’s convenient to our customers and, through this, create increased access for patients.”

IntelliMax enables remote as well as onsite proactive system maintenance. In 2020, IntelliMax ensured that more than 200,000 patient treatment slots could continue without interruption.

“This patent for Elekta service is a fantastic milestone on our digitalization journey,” adds Paul Bergström. “It is the first of several pending patent applications focused on improving the serviceability of our solutions. We are going to improve the ‘predictability-to-treat’ for customers – in other words, giving them the certainty that the treatment system is available for clinical use if and when they need it for life-saving, life-prolonging cancer treatments.”

Learn more about IntelliMax at [elekta.com/IntelliMax](https://elekta.com/IntelliMax).

###

**For further information, please contact:**

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: [Mattias.Thorsson@elekta.com](mailto:Mattias.Thorsson@elekta.com)

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: [Raven.Canzeri@elekta.com](mailto:Raven.Canzeri@elekta.com)

Time zone: ET: Eastern Time



---

### **About Elekta**

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit [elekta.com](http://elekta.com) or follow @Elekta on Twitter.